Use of Lecithin As an Antistatic Agent in Nonconductive Crystallization Slurries for Isolating Pure Active Pharmaceutical Ingredients

被引:3
|
作者
Lee, Ivan Hao [1 ]
机构
[1] Merck & Co Inc, Chem Proc Dev & Commercializat, Rahway, NJ 07065 USA
关键词
SURFACTANT; ALVEOLAR;
D O I
10.1021/op4001065
中图分类号
O69 [应用化学];
学科分类号
081704 ;
摘要
Static buildup in glass-lined processing train during pure API crystallizations in organic solvents can result in costly glass damage to the vessel internals, and presents a potential safety risk of fire or explosion. The propensity for static buildup is directly related to the conductivity of the solvent system and is especially high for nonpolar organic solvents such as toluene and heptane. Lecithin is a zwitterionic organic surfactant commonly used in the food and pharmaceutical industry. Lecithin has been proposed as an antistatic agent due to its relatively high solubility in nonpolar organic solvents, as well as its charge carrying capabilities when dissolved. Because lecithin is routinely used in the pharmaceutical industry including in final drug product formulations, it has the advantage of having a reduced regulatory hurdle for implementation during API processing relative to other commercial antistatic agents that do not have precedence for pharmaceutical applications. Experimental results show that addition of lecithin at ppm levels is sufficient to increase solution and pure API slurry conductivity to above an acceptable threshold that reduces the risk of static charge buildup with a linear relationship between conductivity and lecithin concentration demonstrated. Noteworthy is the observation that the amount of lecithin required is related to the surface area of the API solids, as sufficient lecithin must be added to coat the solid surface with approximately monolayer coverage before the excess lecithin is solvated and electrically active in solution. Finally, head-to-head comparison studies with and without lecithin for three API compounds have shown that lecithin does not significantly impact the crystallization process or the physical properties of the API generated.
引用
收藏
页码:1330 / 1334
页数:5
相关论文
共 50 条
  • [2] Polymorphism and Crystallization of Active Pharmaceutical Ingredients (APIs)
    Lu, Jie
    Rohani, Sohrab
    CURRENT MEDICINAL CHEMISTRY, 2009, 16 (07) : 884 - 905
  • [3] From form to function: Crystallization of active pharmaceutical ingredients
    Variankaval, Narayan
    Cote, Aaron S.
    Doherty, Michael F.
    AICHE JOURNAL, 2008, 54 (07) : 1682 - 1688
  • [4] Process Analytical Technology for Crystallization of Active Pharmaceutical Ingredients
    Malwade, Chandrakant R.
    Qu, Haiyan
    CURRENT PHARMACEUTICAL DESIGN, 2018, 24 (21) : 2456 - 2472
  • [5] Crystallization of Microparticulate Pure Polymorphs of Active Pharmaceutical Ingredients Using CO2-Expanded Solvents
    Sala, Santiago
    Cordoba, Alba
    Moreno-Calvo, Evelyn
    Elizondo, Elisa
    Munto, Maria
    Elena Rojas, Paula
    Angels Larrayoz, Maria
    Ventosa, Nora
    Veciana, Jaume
    CRYSTAL GROWTH & DESIGN, 2012, 12 (04) : 1717 - 1726
  • [6] Compact Crystallization, Filtration, and Drying for the Production of Active Pharmaceutical Ingredients
    Wong, Shin Yee
    Chen, Jie
    Forte, Laura E.
    Myerson, Allan S.
    ORGANIC PROCESS RESEARCH & DEVELOPMENT, 2013, 17 (04) : 684 - 692
  • [7] Pervaporation-assisted crystallization of active pharmaceutical ingredients (APIs)
    Schmitz, Claire
    Hussain, Mohammed Noorul
    Meers, Tom
    Xie, Zongli
    Zhu, Liping
    Van Gerven, Tom
    Yang, Xing
    ADVANCED MEMBRANES, 2023, 3
  • [8] Supramolecular Metal-Phenolic Gels for the Crystallization of Active Pharmaceutical Ingredients
    Rahim, Md Arifur
    Hata, Yuuki
    Bjornmalm, Mattias
    Ju, Yi
    Caruso, Frank
    SMALL, 2018, 14 (26)
  • [9] High-throughput nanoscale crystallization of dihydropyridine active pharmaceutical ingredients
    Metherall, Jessica P.
    Corner, Philip A.
    McCabe, James F.
    Hall, Michael J.
    Probert, Michael R.
    Acta Crystallographica Section B: Structural Science, Crystal Engineering and Materials, 2024, 80 (Pt 1) : 4 - 12
  • [10] Classification of the Crystallization Behavior of Amorphous Active Pharmaceutical Ingredients in Aqueous Environments
    Van Eerdenbrugh, Bernard
    Raina, Shweta
    Hsieh, Yi-Ling
    Augustijns, Patrick
    Taylor, Lynne S.
    PHARMACEUTICAL RESEARCH, 2014, 31 (04) : 969 - 982